Itoco (ITMC) Capital Expenditure : $0.00 Mil (TTM As of Sep. 2010)

View and export this data going back to 2009. Start your Free Trial

What is Itoco Capital Expenditure?

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Itoco's cash flow for capital expenditures for the three months ended in Sep. 2010 was $0.00 Mil. Its cash flow for capital expenditures for the trailing twelve months (TTM) ended in Sep. 2010 was $0.00 Mil.

Itoco Capital Expenditure Historical Data

The historical data trend for Itoco's Capital Expenditure can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Itoco Capital Expenditure Chart

Itoco Annual Data

Trend

Dec08

Dec09

Capital Expenditure

-3.46

Itoco Quarterly Data
	Mar08	Jun08	Sep08	Dec08	Mar09	Jun09	Sep09	Dec09	Mar10	Jun10	Sep10
Capital Expenditure	Get a 7-Day Free Trial						-	-	-	-	-

Itoco Capital Expenditure Calculation

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Capital Expenditure for the trailing twelve months (TTM) ended in Sep. 2010 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Itoco (ITMC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Itoco Inc (OTCPK:ITMC) » Definitions » Capital Expenditure

Comparable Companies

Traded in Other Exchanges

N/A

Address

50 West Liberty Street, Suite 880, Reno, NV, USA, 89501

Website

https://www.itoco.net

Itoco Inc is focused on developing and bringing biotech products to the market via co-development and joint venture arrangements with various companies. The company is currently examining various technologies that seek to control and/or identify bio-contaminants such as viruses and bacteria.